A mandatory CMS model will tie heart failure outcomes to reimbursement starting in 2027. Here’s what it covers and how to get ahead of it.
Starting January 1, 2027, CMS will require selected cardiologists to participate in the Ambulatory Specialty Model (ASM), a mandatory program that ties heart failure outcomes and costs directly to Medicare reimbursement. Payment adjustments begin in 2029, starting at up to ±9% of Part B claims and rising to as much as ±12% by the model's final performance year.
What Is the Ambulatory Specialty Model?
The ASM is a mandatory CMS payment model aimed at high-cost chronic conditions, starting with heart failure and lower back pain. The idea is simple: reward practices that keep patients stable and out of the hospital and reduce payment for those that don’t. Patients with heart failure account for an estimated $179.5 billion in annual U.S. healthcare spending, so it was an obvious first target. The program runs for five performance years, through 2031.
Who’s Affected, and When?
CMS named more than 2,600 cardiologists on its initial participant list, and many were added automatically based on geography and specialty coding. Participation isn’t optional for those clinicians. A few key dates:
2027: Performance tracking begins on January 1.
2029: The first payment adjustments take effect, starting at up to ±9% of Part B claims (rising to ±12% by the final performance year).
2031: The five-year model concludes.
Worth checking: some interventional cardiologists and electrophysiologists have appeared on the list due to coding issues, even though CMS says they shouldn’t be there. Confirm your roster early.
What Will Cardiologists Be Measured On?
CMS is still finalizing details, but evaluation falls into four areas: quality, cost, care improvement activities, and interoperability (using certified EHR technology). Here's what that means in practice for cardiology:
1. Quality. Unplanned heart failure hospitalizations, and whether patients with reduced ejection fractions are on guideline-directed medical therapy (GDMT) — beta blockers, ACE inhibitors, and related medications.
2. Cost. Total heart failure-related spending is attributed to your patients, including ED visits, admissions, and medications, even when those happen outside your direct control.
3. Patient-reported outcomes. Standardized surveys that capture how patients say they are feeling and functioning, such as the Kansas City Cardiomyopathy Questionnaire (KCCQ). The KCCQ is licensed through Outcomes Instruments, LLC, so line up access early.
How Should Practices Prepare?
It comes down to one thing: visibility or seeing patient risk early enough to act on it. Most practices aren’t short on data; they’re short on the time to sort through it. Start by confirming which of your physicians are on the list, then ask whether your team can reliably identify high-risk patients, track GDMT, capture patient-reported outcomes, and catch warning signs between visits.
That’s where remote monitoring earns its place in your value-based strategy. The early signals of decompensation, a rhythm change, a device transmission, a shift in symptoms, usually show up before an avoidable admission. They only help if your team can spot them in time and isn’t buried under transmission overload.
Octagos was built for exactly this. Our Atlas AI and IBHRE-certified clinicians archive more than half of incoming transmissions and surface only the actionable, billable alerts your team needs, so the right patients get attention sooner, documentation stays clean, and your staff isn’t fighting alert fatigue. See how our heart failure monitoring works, or explore the full platform for cardiology practices.
The ASM is one more sign that cardiac care is being measured on outcomes, not just encounters. The practices that build visibility now will be ready in 2027.
If that’s the direction you’re headed, we’d love to help you get there. Talk to the Octagos team.
Frequently Asked Questions
When does the Ambulatory Specialty Model start?
Performance tracking begins January 1, 2027. Payment adjustments tied to that performance start in 2029, and the model runs through 2031.
Is ASM participation mandatory?
Yes. Unlike past CMS demonstration programs, the ASM is required for cardiologists practicing in selected geographic areas, and many were added to the list automatically.
How much can the ASM affect reimbursement?
Adjustments are two-sided and grow over time, starting at up to ±9% in 2029 (based on 2027 performance) and rising to ±10%, ±11%, and ±12% by the final performance year in 2031.
What conditions does the ASM cover?
It launches with two high-cost chronic conditions: heart failure and low back pain.
How does remote monitoring help with the ASM?
It gives care teams earlier visibility into patient decline, supports GDMT and clean documentation, and helps reduce the avoidable hospitalizations the model penalizes. Platforms like Octagos cut transmission overload so teams can focus on the patients who need action.